Sage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by StockNews.com

Sage Therapeutics (NASDAQ:SAGE) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday.

SAGE has been the subject of a number of other reports. JPMorgan Chase & Co. lifted their price objective on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 26th. Morgan Stanley boosted their target price on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Royal Bank of Canada boosted their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a “sector perform” rating in a research report on Thursday, February 15th. Scotiabank reduced their target price on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating for the company in a research report on Thursday. Finally, HC Wainwright reissued a “neutral” rating and issued a $28.00 target price on shares of Sage Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $39.28.

Sage Therapeutics Price Performance

SAGE stock traded up $0.29 during midday trading on Friday, reaching $13.33. 1,258,722 shares of the company were exchanged, compared to its average volume of 1,009,849. The business has a 50-day moving average price of $19.85 and a two-hundred day moving average price of $20.91. Sage Therapeutics has a one year low of $10.92 and a one year high of $59.99. The firm has a market capitalization of $801.27 million, a price-to-earnings ratio of -1.47 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. During the same period in the previous year, the business posted ($2.47) earnings per share. The company’s revenue for the quarter was up 2621.5% compared to the same quarter last year. As a group, analysts anticipate that Sage Therapeutics will post -6.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SAGE. CWM LLC lifted its position in Sage Therapeutics by 274.2% during the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 883 shares during the period. KBC Group NV acquired a new position in Sage Therapeutics during the fourth quarter worth about $28,000. China Universal Asset Management Co. Ltd. raised its stake in Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 748 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Sage Therapeutics during the first quarter worth about $34,000. Finally, Tower Research Capital LLC TRC raised its stake in Sage Therapeutics by 74.0% during the third quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 2,148 shares in the last quarter. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.